Search
Creatine
go.drugbank.com/drugs/DB00148ApprovedInvestigationalNutraceuticalAn amino acid derivative that occurs in vertebrate tissues and in urine. In muscle tissue, creatine generally occurs as phosphocreatine. Creatine is excreted as creatinine in the urine.
Tranylcypromine
go.drugbank.com/drugs/DB00752ApprovedInvestigationalAn irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).
Synonyms: dl-tranylcypromine, trans-DL-2-PhenylcyclopropylamineCX-052075
go.drugbank.com/drugs/DB31655Approved[L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from
Sertaconazole
go.drugbank.com/drugs/DB01153ApprovedSertaconazole nitrate is an antifungal medication of the imidazole class. It is available in topical formulations for the treatment of skin infections such as athlete's foot.
Metyrapone
go.drugbank.com/drugs/DB01011ApprovedInvestigationalAn inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.
Cerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigational[L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency. … [A264354, A264369] As a recombinant human TPP1, cerliponase alfa is used as an enzyme replacement therapy to restore the levels of TPP1 in patients with CLN2.[L51339]
Inulin
go.drugbank.com/drugs/DB00638ApprovedInvestigationalNutraceuticalA starch found in the tubers and roots of many plants. Since it is hydrolyzable to fructose, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function.
Mirikizumab
go.drugbank.com/drugs/DB14910ApprovedInvestigational[L46237] In April 2023, the US FDA declined to approve mirikizumab for the treatment of ulcerative colitis on the basis of manufacturing concerns. … [L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and was eventually approved in the US in October 2023[L48651] for the treatment of adult patients with
LM-609
go.drugbank.com/drugs/DB05787ExperimentalLM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood vessels, as well as on certain tumors.